Does Xgeva Cause Low Calcium?
Yes, Xgeva (denosumab) can cause hypocalcemia, or low blood calcium levels. This is a known risk listed in its prescribing information, occurring because the drug inhibits osteoclasts that break down bone, reducing calcium release into the blood.[1] Clinical trials showed hypocalcemia in 13-17% of patients, often within weeks of starting treatment, with severe cases (calcium below 7 mg/dL) in about 3%.[2]
How Common Is Low Calcium with Xgeva?
Rates vary by dose and patient factors. In studies for bone metastases, any-grade hypocalcemia hit 17% versus 6% on placebo; severe cases were 1.7% versus 0.6%. For osteoporosis prevention post-cancer, rates reached 10%.[1][2] Risk rises with higher doses, kidney issues, low vitamin D, or magnesium deficiency.
Why Does Xgeva Lower Calcium Levels?
Xgeva blocks RANKL, a protein osteoclasts need to resorb bone and release calcium. This slows bone turnover, dropping serum calcium. Unlike bisphosphonates, effects start fast—often in 1-2 weeks—due to potent RANKL inhibition.[1]
What Symptoms Should Patients Watch For?
Early signs include muscle cramps, tingling in fingers/toes, numbness, seizures, or irregular heartbeat. Severe hypocalcemia can lead to hospitalization. Patients often need calcium and vitamin D supplements before and during treatment to prevent this.[1][2]
How Do Doctors Manage Low Calcium on Xgeva?
Guidelines recommend baseline calcium checks, daily supplements (at least 1000 mg calcium, 400 IU vitamin D), and monitoring levels every 1-2 weeks initially, then monthly. If levels drop below 8.5 mg/dL, increase supplements or pause dosing. Kidney patients get extra scrutiny.[1]
How Does Xgeva Compare to Other Bone Drugs on Calcium Risk?
Xgeva has higher hypocalcemia rates than bisphosphonates like Zometa (zoledronic acid), where severe cases are under 2%.[2] Prolia, the lower-dose denosumab version for osteoporosis, shows similar but slightly lower rates (9% any-grade).[1] Switching from IV bisphosphonates to Xgeva can spike risk temporarily.
Who Is Most at Risk?
Patients with chronic kidney disease (especially stage 4+), hypoparathyroidism, recent bisphosphonate use, or poor nutrition face higher odds. Cancer patients on Xgeva for bone metastases see more events than those on it for giant cell tumor.[2]
[1]: Xgeva Prescribing Information (Amgen)
[2]: FDA Label for Xgeva